tetano
Editor, Senior Moderator
Antiviral Res
. 2021 Jul 12;105137.
doi: 10.1016/j.antiviral.2021.105137. Online ahead of print.
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
Franck Touret[SUP] 1 [/SUP], Jean-Sélim Driouich[SUP] 2 [/SUP], Maxime Cochin[SUP] 2 [/SUP], Paul Rémi Petit[SUP] 2 [/SUP], Magali Gilles[SUP] 2 [/SUP], Karine Barthélémy[SUP] 2 [/SUP], Grégory Moureau[SUP] 2 [/SUP], Francois-Xavier Mahon[SUP] 3 [/SUP], Denis Malvy[SUP] 4 [/SUP], Caroline Solas[SUP] 5 [/SUP], Xavier de Lamballerie[SUP] 2 [/SUP], Antoine Nougairède[SUP] 2 [/SUP]
Affiliations
Abstract
Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of Imatinib in multiple models. Our results indicated that Imatinib and another TKI, the Masitinib, exhibit an antiviral activity in VeroE6 cells. However, Imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, Imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of Imatinib and similar TKIs as antivirals in the treatment of Covid-19.
Keywords: Antivirals; Coronavirus; Covid-19; Imatinib; SARS-CoV-2; Tyrosine kinase inhibitor.
. 2021 Jul 12;105137.
doi: 10.1016/j.antiviral.2021.105137. Online ahead of print.
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
Franck Touret[SUP] 1 [/SUP], Jean-Sélim Driouich[SUP] 2 [/SUP], Maxime Cochin[SUP] 2 [/SUP], Paul Rémi Petit[SUP] 2 [/SUP], Magali Gilles[SUP] 2 [/SUP], Karine Barthélémy[SUP] 2 [/SUP], Grégory Moureau[SUP] 2 [/SUP], Francois-Xavier Mahon[SUP] 3 [/SUP], Denis Malvy[SUP] 4 [/SUP], Caroline Solas[SUP] 5 [/SUP], Xavier de Lamballerie[SUP] 2 [/SUP], Antoine Nougairède[SUP] 2 [/SUP]
Affiliations
- PMID: 34265358
- DOI: 10.1016/j.antiviral.2021.105137
Abstract
Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of Imatinib in multiple models. Our results indicated that Imatinib and another TKI, the Masitinib, exhibit an antiviral activity in VeroE6 cells. However, Imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, Imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of Imatinib and similar TKIs as antivirals in the treatment of Covid-19.
Keywords: Antivirals; Coronavirus; Covid-19; Imatinib; SARS-CoV-2; Tyrosine kinase inhibitor.